About us

History

Ai2 spun out of Dr Curtis Dobson's research at the University of Manchester. This work showed that a human protein, apolipoprotein E, unexpectedly contained a small region with rich anti-infective activity, which could be harnessed in a family of peptides. The company was incorporated in 2005, and is now based in state of the art laboratories within the University campus.

Ai2 Ltd. won the prestigious North West Biotechnology Project of the Year Award for 2004, and was voted North West Biotechnology Company of the Year for 2005. The company has received substantial investment and grant income within the last two years, securing around £2.5m to develop its technology. Ai2's peptides are the subject of the EC-funded NPARI consortium, established to combat various types of resistant infection.

Mission

Ai2's high quality management team have prioritized medical device infection as a key unmet clinical need, with this being preventable using Ai2 peptide coatings. Prototype devices featuring Ai2 technology show no cytotoxicity (unlike many existing silver based anti-infective coatings), and are resistant to the development of microbial resistance. Ai2's protein-based approach is highly efficacious (compared even with other antimicrobial peptides), cost-effective and can easily be applied to a range of surfaces.

Ai2 is striving for truly infection-free medical devices , one of the most exciting developments in this sector in decades. Our USP is the combination of powerful anti-infective action with biocompatibilty, enabling Ai2 to consolidate its position as a key player in the anti-infective medical device sector.

Ai2 is currently working with a broad range of medical device manufacturers, in order to clearly add value to existing products by providing the best available solution to the unmet need of medical device infection.